The market treats this drug company’s next product updates as almost worthless, even though its lead infection-fighting catheter lock is already widely used and protected for years. The big question is whether upcoming study results and a planned payment reset can lift the business back into favor—or whether a failed trial and a few large customers pulling back could hit hard.Read more
CorMedix aims to build a growing infection-prevention business as its DefenCath product spreads through dialysis clinics and it pushes into other high-need patient groups. The big upside comes from new uses and a second drug that could broaden its reach, but delays in clinical results, payer pushback, or integration missteps could slow the story.Read more
CorMedix is trying to turn itself into a broader infection-fighting drug business by buying Melinta and leaning on its hospital sales network to push newer treatments. The upside is faster adoption as hospitals focus on preventing costly infections, but the plan could stumble if the merger proves messy, regulators slow approvals, or debt and price pressure squeeze results.Read more
Catalysts About CorMedix CorMedix develops and commercializes specialty therapies that prevent and treat life threatening infections in high risk hospital and clinic patients. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
